Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton’s tyrosine kinase inhibitor

This is the authors' abstract. We don't add key points for this paper.

Adverse events of Bruton's tyrosine kinase inhibitors (BTKis) used in the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies commonly include ecchymoses, purpura, and petechiae. Although second-generation BTKi are more selective than the first-generation BTKi, low-grade bleeding adverse events occur at similar rates in approximately one-third of patients.1 Several case reports describe an extensive ecchymotic patch on sun-exposed extremities in patients treated with BTKi, suggesting the role of repeated microtrauma and UV exposure.